Identification of a novel fusion Iduronidase with improved activity in the cardiovascular system

Keyphrases

• α-L-iduronidase 100%
• Cardiovascular System 100%
• Improved Activity 100%
• Novel Fusion 100%
• Activity Level 40%
• Lysosomal Disease 26%
• Photosystem II 26%
• Central Nervous System 20%
• Enzyme Activity 20%
• Amino Acids 13%
• Gene Therapy 13%
• Area under the Curve 13%
• Current Therapies 13%
• Cardiac Valves 13%
• Disease Pathology 6%
• Pharmacokinetics 6%
• Disease Model 6%
• Enzyme Replacement Therapy 6%
• Novel Genes 6%
• Plasmid 6%
• Complementary DNA (cDNA) 6%
• High Activity 6%
• Gene Delivery 6%
• Antitrypsin 6%
• Rare Genetic Disease 6%
• Major Contributor 6%
• Noncompartmental 6%
• Multisystem Disease 6%
• Liver-specific 6%
• Tail Vein 6%
• Codon Optimization 6%
• CB1 Receptor 6%
• Protein S Deficiency 6%
• Enzyme Assay 6%
• Neurodevelopmental Deficits 6%
• Enzyme Deficiency 6%
• Fusion Enzyme 6%
• Cardiac Valvular Disease 6%

Biochemistry, Genetics and Molecular Biology

• Iduronidase 100%
• Enzyme 26%
• Enzyme Activity 26%
• Hurler Syndrome 20%
• Blood Plasma 20%
• Gene Therapy 13%
• Amino Acids 13%
• Genetics 6%
• Wild Type 6%
• Plasmid 6%
• Gene Targeting 6%
• Promoter Region 6%
• Target Tissue 6%
• Codon 6%
• Pharmacokinetics 6%

Pharmacology, Toxicology and Pharmaceutical Science

• Levo Iduronidase 100%
• Disease 40%
• Hurler Syndrome 20%
• Amino Acid 13%
• Replacement Therapy 6%
• Trypsin Inhibitor 6%
• Receptor 6%
• Systemic Disease 6%
• Cannabinoid 1 Receptor 6%
• Protein Deficiency 6%
• Enzyme Deficiency 6%
• Gene Delivery 6%
• Complementary DNA 6%
• Disease Model 6%
• Pharmacokinetics 6%